Targeting the Wnt/β-catenin//KCNQ1OT1/miR-7-5p/ACVRL1/GPX2 biological axis has the potential to be an attractive method for addressing mTKI resistance in CRC. This evidence concerns the gene KCNQ1OT1 and colorectal carcinoma.